TABLE 1

Patient demographics and clinical characteristics

Patients n206
Age years59±15
Female %65
BMI kg·m−225±5
Smoking status %
Current1
Ex23
Never76
Bronchiectasis aetiology %
Idiopathic41
Post-infective27
Immunodeficiency11
ABPA8
Other#13
Spirometry
FEV1 % pred (range)75±28 (18.1–150.7)
FVC % pred91±25
FEV1/FVC66±14
Sputum colonisation with microorganisms %
Pseudomonas aeruginosa26
Other24
None61
Exacerbations in past 12 months %
013
112
215
317
411
510
 >522
Hospitalisations in last 12 months %
079
111
24
31
42
51
 >52
Comorbidities+ %
Asthma25
Rhinosinusitis23
Cardiovascular14
COPD9
Lung surgery6
Diabetes mellitus4
Lung fibrosis/sarcoidosis3
Malignancy1
Respiratory symptoms
VAS Dyspnoea27 (10–53)
VAS Cough28 (12–53)
VAS Sputum30 (11–56)
SGRQ
SGRQ Total43±20
SGRQ Activities50±27
SGRQ Symptoms63±21
SGRQ Impact33±20
  • Data presented as mean±sd or median (interquartile range), unless otherwise stated. BMI: body mass index; ABPA: allergic bronchopulmonary aspergillosis; FEV1: forced expiratory volume in 1 s; FVC: forced vital capacity; COPD: chronic obstructive pulmonary disease; VAS: visual analogue scale; SGRQ: St George's Respiratory Questionnaire. #: other aetiologies (total n=27) consist of primary ciliary dyskinesia (n=10), Kartagener's syndrome (n=2), inflammatory bowel disease (n=5), rheumatoid arthritis (n=6), Young's syndrome (n=3) and yellow nails syndrome (n=1); : sputum colonisation status does not add up to 100% as participants could be chronically infected with P. aeruginosa and other microorganisms (sputum bacteria colonisation was assessed and defined as at least two positive cultures, a minimum 3 months apart and within 1 year); +: comorbidities do not add up to 100% as participants could have no comorbidities or more than one comorbidities.